Update in Neurodegeneration with Brain Iron Accumulation: Advances in Molecular Diagnosis and Treatment Strategies

Abstract

Neurodegeneration with brain iron accumulation (NBIA) is an umbrella term used to clinically describe a group of neurologic conditions associated with high brain iron. To date, there are 10 genetic subtypes described, which share several common clinical features. Novel technologies such as improved magnetic resonance imaging techniques and whole exome sequencing have provided new clinical and genetic insight into these disorders, thereby improving clinical diagnosis for patients. Indeed, precise diagnosis is now possible for approximately 60% of patients with NBIA. Despite these genetic advances, little is known about the exact underlying disease pathways governing many forms of NBIA. In fact, for most subtypes, the causative genes and affected proteins are not directly related to iron homeostasis. Management for all subtypes remains mainly supportive and based on a multidisciplinary approach, but there are promising advances in the development of novel therapeutic strategies. Focusing mainly on the newly described NBIA subtypes, we summarize the clinical phenotypes, genetic basis, and postulated pathophysiological disease mechanisms, and propose an NBIA diagnostic pathway to guide clinical testing and genetic councelling.

Keywords

neurodegeneration - mitochondrial membrane protein - β-Propeller protein - fatty acid hydroxylase - phospholipase A2

• References

• 1 Pfefferbaum A, Adalsteinsson E, Rohlfing T, Sullivan EV. MRI estimates of brain iron concentration in normal aging: comparison of field-dependent (FDRI) and phase (SWI) methods. Neuroimage 2009; 47 (2) 493-500
• 2 Lehéricy S, Bardinet E, Poupon C, Vidailhet M, François C. 7 Tesla magnetic resonance imaging: a closer look at substantia nigra anatomy in Parkinson's disease. Mov Disord 2014; 29 (13) 1574-1581
• 3 Graham SF, Nasaruddin MB, Carey M , et al. Age-associated changes of brain copper, iron, and zinc in Alzheimer's disease and dementia with Lewy bodies. J Alzheimers Dis 2014; 42 (4) 1407-1413
• 4 Muller M, Leavitt BR. Iron dysregulation in Huntington's disease. J Neurochem 2014; 130 (3) 328-350
• 5 Hayflick SJ, Hartman M, Coryell J, Gitschier J, Rowley H. Brain MRI in neurodegeneration with brain iron accumulation with and without PANK2 mutations. AJNR Am J Neuroradiol 2006; 27 (6) 1230-1233
• 6 Baumeister FA, Auer DP, Hörtnagel K, Freisinger P, Meitinger T. The eye-of-the-tiger sign is not a reliable disease marker for Hallervorden-Spatz syndrome. Neuropediatrics 2005; 36 (3) 221-222
• 7 Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 2001; 28 (4) 345-349
• 8 Levi S, Finazzi D. Neurodegeneration with brain iron accumulation: update on pathogenic mechanisms. Front Pharmacol 2014; 5: 99
• 9 Khan AO, AlDrees A, Elmalik SA , et al. Ophthalmic features of PLA2G6-related paediatric neurodegeneration with brain iron accumulation. Br J Ophthalmol 2014; 98 (7) 889-893
• 10 Romani M, Kraoua I, Micalizzi A , et al. Infantile and childhood onset PLA2G6-associated neurodegeneration in a large North African cohort. Eur J Neurol 2015; 22 (1) 178-186
• 11 Kurian MA, Hayflick SJ. Pantothenate kinase-associated neurodegeneration (PKAN) and PLA2G6-associated neurodegeneration (PLAN): review of two major neurodegeneration with brain iron accumulation (NBIA) phenotypes. Int Rev Neurobiol 2013; 110: 49-71
• 12 Salih MA, Mundwiller E, Khan AO , et al. New findings in a global approach to dissect the whole phenotype of PLA2G6 gene mutations. PLoS One 2013; 8 (10) e76831
• 13 Schneider SA, Hardy J, Bhatia KP. Syndromes of neurodegeneration with brain iron accumulation (NBIA): an update on clinical presentations, histological and genetic underpinnings, and treatment considerations. Mov Disord 2012; 27 (1) 42-53
• 14 Yoshino H, Tomiyama H, Tachibana N , et al. Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism. Neurology 2010; 75 (15) 1356-1361
• 15 Kurian MA, Morgan NV, MacPherson L , et al. Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN). Neurology 2008; 70 (18) 1623-1629
• 16 Gregory A, Polster BJ, Hayflick SJ. Clinical and genetic delineation of neurodegeneration with brain iron accumulation. J Med Genet 2009; 46 (2) 73-80
• 17 Hartig MB, Hörtnagel K, Garavaglia B , et al. Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation. Ann Neurol 2006; 59 (2) 248-256
• 18 Gregory A, Hayflick SJ. Pantothenate kinase-associated neurodegeneration. In: Pagon RA, Adam MP, Ardinger HH, , et al, eds. GeneReviews. Seattle, WA: University of Washington, Seattle; 1993-2015
• 19 Kruer MC, Boddaert N. Neurodegeneration with brain iron accumulation: a diagnostic algorithm. Semin Pediatr Neurol 2012; 19 (2) 67-74
• 20 Alderson NL, Rembiesa BM, Walla MD, Bielawska A, Bielawski J, Hama H. The human FA2H gene encodes a fatty acid 2-hydroxylase. J Biol Chem 2004; 279 (47) 48562-48568
• 21 Potter KA, Kern MJ, Fullbright G , et al. Central nervous system dysfunction in a mouse model of FA2H deficiency. Glia 2011; 59 (7) 1009-1021
• 22 Edvardson S, Hama H, Shaag A , et al. Mutations in the fatty acid 2-hydroxylase gene are associated with leukodystrophy with spastic paraparesis and dystonia. Am J Hum Genet 2008; 83 (5) 643-648
• 23 Dick KJ, Al-Mjeni R, Baskir W , et al. A novel locus for an autosomal recessive hereditary spastic paraplegia (SPG35) maps to 16q21-q23. Neurology 2008; 71 (4) 248-252
• 24 Kruer MC, Paisán-Ruiz C, Boddaert N , et al. Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA). Ann Neurol 2010; 68 (5) 611-618
• 25 Garone C, Pippucci T, Cordelli DM , et al. FA2H-related disorders: a novel c.270+3A>T splice-site mutation leads to a complex neurodegenerative phenotype. Dev Med Child Neurol 2011; 53 (10) 958-961
• 26 Pierson TM, Simeonov DR, Sincan M , et al; NISC Comparative Sequencing Program. Exome sequencing and SNP analysis detect novel compound heterozygosity in fatty acid hydroxylase-associated neurodegeneration. Eur J Hum Genet 2012; 20 (4) 476-479
• 27 Liao X, Luo Y, Zhan Z , et al. SPG35 contributes to the second common subtype of AR-HSP in China: frequency analysis and functional characterization of FA2H gene mutations. Clin Genet 2015; 87 (1) 85-89
• 28 Donkervoort S, Dastgir J, Hu Y , et al. Phenotypic variability of a likely FA2H founder mutation in a family with complicated hereditary spastic paraplegia. Clin Genet 2014; 85 (4) 393-395
• 29 Zöller I, Meixner M, Hartmann D , et al. Absence of 2-hydroxylated sphingolipids is compatible with normal neural development but causes late-onset axon and myelin sheath degeneration. J Neurosci 2008; 28 (39) 9741-9754
• 30 Kruer MC, Gregory A, Hayflick SJ. Fatty acid hydroxylase-associated neurodegeneration. In: Pagon RA, Adam MP, Ardinger HH, , et al, eds. GeneReviews. Seattle, WA: University of Washington, Seattle; 1993. –2015
• 31 Gregory A, Hayflick S. Neurodegeneration with brain iron accumulation disorders overview. Available at: http://www.ncbi.nlm.nih.gov/books/NBK121988 . Accessed February 28, 2013
• 32 Hartig MB, Iuso A, Haack T , et al. Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation. Am J Hum Genet 2011; 89 (4) 543-550
• 33 Hogarth P, Gregory A, Kruer MC , et al. New NBIA subtype: genetic, clinical, pathologic, and radiographic features of MPAN. Neurology 2013; 80 (3) 268-275
• 34 Iuso A, Sibon OC, Gorza M , et al. Impairment of Drosophila orthologs of the human orphan protein C19orf12 induces bang sensitivity and neurodegeneration. PLoS ONE 2014; 9 (2) e89439
• 35 Dogu O, Krebs CE, Kaleagasi H , et al. Rapid disease progression in adult-onset mitochondrial membrane protein-associated neurodegeneration. Clin Genet 2013; 84 (4) 350-355
• 36 Landouré G, Zhu PP, Lourenço CM , et al; NIH Intramural Sequencing Center. Hereditary spastic paraplegia type 43 (SPG43) is caused by mutation in C19orf12. Hum Mutat 2013; 34 (10) 1357-1360
• 37 Gregory A, Hayflick SJ. Genetics of neurodegeneration with brain iron accumulation. Curr Neurol Neurosci Rep 2011; 11 (3) 254-261
• 38 Haack TB, Hogarth P, Kruer MC , et al. Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA. Am J Hum Genet 2012; 91 (6) 1144-1149
• 39 Horvath R. Brain iron takes off: a new propeller protein links neurodegeneration with autophagy. Brain 2013; 136 (Pt 6) 1687-1691
• 40 Saitsu H, Nishimura T, Muramatsu K , et al. De novo mutations in the autophagy gene WDR45 cause static encephalopathy of childhood with neurodegeneration in adulthood. Nat Genet 2013; 45 (4) 445-449 , e1
• 41 Hayflick SJ, Kruer MC, Gregory A , et al. β-Propeller protein-associated neurodegeneration: a new X-linked dominant disorder with brain iron accumulation. Brain 2013; 136 (Pt 6) 1708-1717
• 42 Okamoto N, Ikeda T, Hasegawa T , et al. Early manifestations of BPAN in a pediatric patient. Am J Med Genet A 2014; 164A (12) 3095-3099
• 43 Verhoeven WM, Egger JI, Koolen DA , et al. Beta-propeller protein-associated neurodegeneration (BPAN), a rare form of NBIA: novel mutations and neuropsychiatric phenotype in three adult patients. Parkinsonism Relat Disord 2014; 20 (3) 332-336
• 44 Kruer MC, Boddaert N, Schneider SA , et al. Neuroimaging features of neurodegeneration with brain iron accumulation. AJNR Am J Neuroradiol 2012; 33 (3) 407-414
• 45 Dusi S, Valletta L, Haack TB , et al. Exome sequence reveals mutations in CoA synthase as a cause of neurodegeneration with brain iron accumulation. Am J Hum Genet 2014; 94 (1) 11-22
• 46 Aghajanian S, Worrall DM. Identification and characterization of the gene encoding the human phosphopantetheine adenylyltransferase and dephospho-CoA kinase bifunctional enzyme (CoA synthase). Biochem J 2002; 365 (Pt 1) 13-18
• 47 Tahiliani AG, Beinlich CJ. Pantothenic acid in health and disease. Vitam Horm 1991; 46: 165-228
• 48 Begley TP, Kinsland C, Strauss E. The biosynthesis of coenzyme A in bacteria. Vitam Horm 2001; 61: 157-171
• 49 Bosveld F, Rana A, van der Wouden PE , et al. De novo CoA biosynthesis is required to maintain DNA integrity during development of the Drosophila nervous system. Hum Mol Genet 2008; 17 (13) 2058-2069
• 50 Frucht S. Movement Disorder Emergencies: Diagnosis and Treatment. New York, NY: Humana Press; 2011
• 51 Lumsden DE, Lundy C, Fairhurst C, Lin JP. Dystonia Severity Action Plan: a simple grading system for medical severity of status dystonicus and life-threatening dystonia. Dev Med Child Neurol 2013; 55 (7) 671-672
• 52 Allen NM, Lin JP, Lynch T, King MD. Status dystonicus: a practice guide. Dev Med Child Neurol 2014; 56 (2) 105-112
• 53 McNeill A, Birchall D, Hayflick SJ , et al. T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology 2008; 70 (18) 1614-1619
• 54 Langkammer C, Krebs N, Goessler W , et al. Quantitative MR imaging of brain iron: a postmortem validation study. Radiology 2010; 257 (2) 455-462
• 55 Ghadery C, Pirpamer L, Hofer E , et al. R2* mapping for brain iron: associations with cognition in normal aging. Neurobiol Aging 2015; 36 (2) 925-932
• 56 Crompton D, Rehal PK, MacPherson L , et al. Multiplex ligation-dependent probe amplification (MLPA) analysis is an effective tool for the detection of novel intragenic PLA2G6 mutations: implications for molecular diagnosis. Mol Genet Metab 2010; 100 (2) 207-212
• 57 The Human Gene Mutation Database at the Institute of Medical Genetics in Cardiff. Available at: http://www.hgmd.cf.ac.uk/ac/index.php
• 58 Keogh MJ, Chinnery PF. Current concepts and controversies in neurodegeneration with brain iron accumulation. Semin Pediatr Neurol 2012; 19 (2) 51-56
• 59 Abbruzzese G, Cossu G, Balocco M , et al. A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica 2011; 96 (11) 1708-1711
• 60 Zorzi G, Zibordi F, Chiapparini L , et al. Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial. Mov Disord 2011; 26 (9) 1756-1759
• 61 Pratini NR, Sweeters N, Vichinsky E, Neufeld JA. Treatment of classic pantothenate kinase-associated neurodegeneration with deferiprone and intrathecal baclofen. Am J Phys Med Rehabil 2013; 92 (8) 728-733
• 62 Chinnery PF, Crompton DE, Birchall D , et al. Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain 2007; 130 (Pt 1) 110-119
• 63 Velasco-Sánchez D, Aracil A, Montero R , et al. Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia. Cerebellum 2011; 10 (1) 1-8
• 64 Yang Y, Wu Z, Kuo YM, Zhou B. Dietary rescue of fumble—a Drosophila model for pantothenate-kinase-associated neurodegeneration. J Inherit Metab Dis 2005; 28 (6) 1055-1064
• 65 Rana A, Seinen E, Siudeja K , et al. Pantethine rescues a Drosophila model for pantothenate kinase-associated neurodegeneration. Proc Natl Acad Sci U S A 2010; 107 (15) 6988-6993
• 66 Brunetti D, Dusi S, Giordano C , et al. Pantethine treatment is effective in recovering the disease phenotype induced by ketogenic diet in a pantothenate kinase-associated neurodegeneration mouse model. Brain 2014; 137 (Pt 1) 57-68
• 67 Strokin M, Sergeeva M, Reiser G. Docosahexaenoic acid and arachidonic acid release in rat brain astrocytes is mediated by two separate isoforms of phospholipase A2 and is differently regulated by cyclic AMP and Ca2+. Br J Pharmacol 2003; 139 (5) 1014-1022
• 68 Strokin M, Sergeeva M, Reiser G. Role of Ca2+-independent phospholipase A2 and n-3 polyunsaturated fatty acid docosahexaenoic acid in prostanoid production in brain: perspectives for protection in neuroinflammation. Int J Dev Neurosci 2004; 22 (7) 551-557
• 69 Horrocks LA, Farooqui AA. Docosahexaenoic acid in the diet: its importance in maintenance and restoration of neural membrane function. Prostaglandins Leukot Essent Fatty Acids 2004; 70 (4) 361-372
• 70 Shinzawa K, Sumi H, Ikawa M , et al. Neuroaxonal dystrophy caused by group VIA phospholipase A2 deficiency in mice: a model of human neurodegenerative disease. J Neurosci 2008; 28 (9) 2212-2220
• 71 Haag M. Essential fatty acids and the brain. Can J Psychiatry 2003; 48 (3) 195-203
• 72 Basselin M, Rosa AO, Ramadan E , et al. Imaging decreased brain docosahexaenoic acid metabolism and signaling in iPLA(2)β (VIA)-deficient mice. J Lipid Res 2010; 51 (11) 3166-3173
• 73 Calon F, Lim GP, Yang F , et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 2004; 43 (5) 633-645
• 74 Igarashi M, Gao F, Kim HW, Ma K, Bell JM, Rapoport SI. Dietary n-6 PUFA deprivation for 15 weeks reduces arachidonic acid concentrations while increasing n-3 PUFA concentrations in organs of post-weaning male rats. Biochim Biophys Acta 2009; 1791 (2) 132-139
• 75 Kim HW, Rao JS, Rapoport SI, Igarashi M. Dietary n-6 PUFA deprivation downregulates arachidonate but upregulates docosahexaenoate metabolizing enzymes in rat brain. Biochim Biophys Acta 2011; 1811 (2) 111-117
• 76 Blanchard H, Taha AY, Cheon Y, Kim HW, Turk J, Rapoport SI. iPLA2β knockout mouse, a genetic model for progressive human motor disorders, develops age-related neuropathology. Neurochem Res 2014; 39 (8) 1522-1532
• 77 Castelnau P, Cif L, Valente EM , et al. Pallidal stimulation improves pantothenate kinase-associated neurodegeneration. Ann Neurol 2005; 57 (5) 738-741
• 78 Mikati MA, Yehya A, Darwish H, Karam P, Comair Y. Deep brain stimulation as a mode of treatment of early onset pantothenate kinase-associated neurodegeneration. Eur J Paediatr Neurol 2009; 13 (1) 61-64
• 79 Timmermann L, Pauls KA, Wieland K , et al. Dystonia in neurodegeneration with brain iron accumulation: outcome of bilateral pallidal stimulation. Brain 2010; 133 (Pt 3) 701-712
• 80 Air EL, Ostrem JL, Sanger TD, Starr PA. Deep brain stimulation in children: experience and technical pearls. J Neurosurg Pediatr 2011; 8 (6) 566-574
• 81 Lumsden DE, Kaminska M, Gimeno H , et al. Proportion of life lived with dystonia inversely correlates with response to pallidal deep brain stimulation in both primary and secondary childhood dystonia. Dev Med Child Neurol 2013; 55 (6) 567-574
• 82 Kaminska M, Lumsden DE, Ashkan K, Malik I, Selway R, Lin JP. Rechargeable deep brain stimulators in the management of paediatric dystonia: well tolerated with a low complication rate. Stereotact Funct Neurosurg 2012; 90 (4) 233-239
• 83 Cif L, Kurian MA, Gonzalez V , et al. Atypical PLA2G6-associated neurodegeneration: social communication impairment, dystonia and response to deep brain stimulation. Mov Disord Clin Pract 2014; 2: 128-131
• 84 Biffi A, Montini E, Lorioli L , et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013; 341 (6148) 1233158
• 85 Hwu WL, Muramatsu S, Tseng SH , et al. Gene therapy for aromatic L-amino acid decarboxylase deficiency. Sci Transl Med 2012; 4 (134) 134ra61
• 86 Palfi S, Gurruchaga JM, Ralph GS , et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet 2014; 383 (9923) 1138-1146
• 87 Takahashi K, Tanabe K, Ohnuki M , et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131 (5) 861-872
• 88 Brown ME, Rondon E, Rajesh D , et al. Derivation of induced pluripotent stem cells from human peripheral blood T lymphocytes. PLoS One 2010; 5 (6) e11373
• 89 Qu X, Liu T, Song K, Li X, Ge D. Induced pluripotent stem cells generated from human adipose-derived stem cells using a non-viral polycistronic plasmid in feeder-free conditions. PLoS One 2012; 7 (10) e48161
• 90 Tabar V, Studer L. Pluripotent stem cells in regenerative medicine: challenges and recent progress. Nat Rev Genet 2014; 15 (2) 82-92
• 91 Tuszynski MH, Wang Y, Graham L , et al. Neural stem cells in models of spinal cord injury. Exp Neurol 2014; 261: 494-500
• 92 Rivera FJ, Aigner L. Adult mesenchymal stem cell therapy for myelin repair in multiple sclerosis. Biol Res 2012; 45 (3) 257-268
• 93 Tatarishvili J, Oki K, Monni E , et al. Human induced pluripotent stem cells improve recovery in stroke-injured aged rats. Restor Neurol Neurosci 2014; 32 (4) 547-558
• 94 Kriks S, Shim JW, Piao J , et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 2011; 480 (7378) 547-551
• 95 Aubry L, Bugi A, Lefort N, Rousseau F, Peschanski M, Perrier AL. Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats. Proc Natl Acad Sci U S A 2008; 105 (43) 16707-16712
• 96 ClinicalTrials.gov registry and results database of publicly and privately supported clinical studies of human participants conducted around the world: Available at: https://clinicaltrials.gov